Losmapimod
FIS-001-2019
Phase 2 small_molecule active
Quick answer
Losmapimod for Facioscapulohumeral Muscular Dystrophy 1 (FSHD1) is a Phase 2 program (small_molecule) at Fulcrum Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Fulcrum Therapeutics
- Indication
- Facioscapulohumeral Muscular Dystrophy 1 (FSHD1)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active